FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1701-1702 November 25, 1999 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Brisinda, G. Related Article by Arndt, C. A.S.

To the Editor: The review by Arndt and Crist (July 29 issue)¹ underplays the role of stem-cell transplantation in the treatment of Ewing's sarcoma. Our group has worked on stem-cell transplantation in Ewing's sarcoma since the early 1980s and has published data demonstrating a two-year survival rate of approximately 70 percent among patients presenting with metastasis, large lesions (those more than 8 cm), or both, at diagnosis.² Follow-up data since 1990 show 60 percent survival at 1 to 11 years among 40 such high-risk patients. These results should be considered promising.

Several developments, however, suggest that stem-cell transplantation may become . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.